Articles tagged with Interferons
A new combination therapy of daily consensus interferon and ribavirin is effective for some people with chronic hepatitis C, particularly those with lower fibrosis scores. Nearly half of all HCV patients do not respond to standard therapy, and this treatment shows promise as an alternative.
A new study suggests that adding a steroid drug to multiple sclerosis (MS) treatment can significantly reduce disease activity. Researchers found that participants who received both the steroid and interferon beta-1a had 38% fewer relapses than those receiving only the interferon drug.
A new study found that adding oral methylprednisolone to interferon beta-1a therapy significantly reduces the relapse rate in patients with relapsing-remitting multiple sclerosis. The treatment was associated with a threefold lower relapse rate compared to placebo.
Locteron showed a significant reduction in flu-like symptoms compared to PEG-Intron, with patients experiencing an 80% lower severity score. The trial demonstrated comparable anti-viral effects and tolerability with the controlled-release interferon alpha.
A new study found that African Americans have lower rates of successful hepatitis C virus (HCV) therapy due to differences in antiviral activity induced by interferon. Early viral kinetic measurements within 24-48 hours of treatment can predict ultimate response rates.
Researchers at UT Southwestern Medical Center found no difference in liver disease progression among patients treated with interferon compared to those who did not receive it. The HALT-C Trial showed that interferon, often used as a maintenance treatment, is ineffective in slowing disease progression.
UT Southwestern researchers found that interferon and another signaling protein are needed to create memory cells that remember how to fight off the virus. Without these cells, the body is defenseless against re-infections.
According to a study published in Archives of Neurology, only about half of patients with multiple sclerosis (MS) achieve and maintain a response to interferon beta treatment over three years. Regular MRI evaluations show that many patients experience worsening disease despite treatment.
A phase III study found that pegylated interferon alfa-2b significantly improved recurrence-free survival in stage III melanoma patients, with a median treatment duration of one year. The treatment reduced the risk of recurrence by 18% and was associated with serious adverse events such as fatigue, liver toxicity, and depression.
A study published in the World Journal of Gastroenterology found that Pakistani patients with genotype-3 HCV who achieve rapid virological response (RVR) within four weeks of therapy are more likely to achieve sustained virological response (SVR). Patients with initial high levels of ALT were also more likely to attain RVR.
The COPILOT study found that low-dose peginterferon alfa-2b improved disease-free survival in patients with cirrhosis and portal hypertension, especially those who stayed on treatment. In contrast, the medication was not superior to colchicine in overall patient populations.
Researchers compared DNA of patients with reduced MS symptoms to those experiencing relapses, identifying key genetic markers associated with treatment response. The study's findings may help predict which treatments will work best for individual patients.
Bevacizumab plus interferon improves progression-free survival in patients with metastatic renal cell carcinoma compared to interferon alone. The new treatment option is expected to provide a better prognosis for patients with renal cancer.
A national study found that long-term pegylated interferon does not prevent the progression of liver disease in patients who haven’t responded to previous treatments. Despite significant viral level decrease and inflammation reduction, 34.1% of treated patients experienced worsening outcomes.
The Phase 2b study demonstrated that Albuferon achieved at least comparable efficacy and safety to peginterferon alfa-2a with a dosing regimen requiring half as many injections. Additionally, Albuferon showed less impairment of health-related quality of life on treatment.
A 24-week course of interferon-alpha therapy after curative treatment for HCV-associated HCC significantly reduces tumor recurrence rates and improves patient survival compared to those without interferon therapy. Patients who achieved a sustained virological response also exhibit improved liver function and prolonged overall survival.
A weight-based dosage of ribavirin improved treatment outcomes in patients with chronic hepatitis C, particularly those who are African-American. The study found that response rates increased as body weight increased, suggesting a potential need to tailor dosing to individual patients.
A study of 468 multiple sclerosis patients found that early treatment with interferon beta-1b can prevent disabling condition development. Early treatment reduced the risk of confirmed disability and clinically definite multiple sclerosis by 41%.
Researchers discovered that PKR enzyme plays a crucial role in the antiviral effect of interferon against some viruses. They found that PKR affects protein synthesis and apoptosis, leading to reduced cell death and viral replication in response to stimuli.
A new study analyzed predictors of sustained virologic response (SVR) in patients with hepatitis C virus (HCV) infection. The results identified several independent factors that impact SVR, including low levels of HCV in the blood, absence of cirrhosis, and genotype other than genotype 1. Patients treated with pegylated interferon alfa...
Researchers found that patients with higher levels of protein S-100 in their serum samples had a greater likelihood of melanoma returning after treatment. The study identified S-100 as a potential biomarker for predicting disease recurrence and stratifying patients into those more or less likely to relapse.
A phase III clinical study shows temsirolimus improves overall survival in patients with advanced renal cell carcinoma compared to standard treatment interferon. The treatment was also better tolerated, with fewer severe side effects.
Researchers found that immune cells in most people with melanoma fail to respond properly to interferon, leading to impaired immune function. This discovery could pave the way for more effective treatment options, including vaccine therapies.
Interferon gamma and interleukin-1 alpha molecules work together, collaborating like two halves of a key, to initiate various immune responses. This unexpected collaboration enhances the antiviral activity of interferon gamma, providing an extra layer of security for the body.
A study found that a combination of pegylated interferon and ribavirin achieved better results than standard therapy in patients with recurrent hepatitis C after liver transplantation. The treatment was more effective, especially when patients showed an early decline in viral load.
Researchers discovered statins inhibit HCV replication without killing host cells. Fluvastatin showed strongest effect in combination with interferon, leading to effective HCV RNA replication inhibition.
Researchers found that suppressing interferon-gamma can prevent damage to myelin-producing cells in the nervous system. Transgenic mice with SOCS1 gene showed reduced symptoms and cell loss compared to those without it.
Researchers found that interferon treatment correlates with signaling proteins STAT1 and STAT3, which can be used as biomarkers to predict melanoma risk. The study suggests that these markers could help identify patients most likely to benefit from specific doses of interferon therapy.
Researchers found that 56% of older HCV patients experienced dose reductions or discontinuations due to adverse effects, negatively impacting sustained virological response rates. The study emphasizes the need for modified treatment schedules and patient education to improve outcomes for this vulnerable population.
A new study conducted at Ohio State University found that combining the immune substances IL-12 and interferon is safe for patients with advanced cancer. The treatment combination was shown to stop disease progression in five patients for at least six months, with no serious side effects reported.
A new study by Regino González-Peralta and colleagues found that interferon in combination with ribavirin is an effective treatment for childhood chronic hepatitis C, with sustained virologic response rates higher than those using interferon alone. Common side effects were mild, but severe adverse events occurred in some children.
Researchers have developed a method to enhance the responsiveness of Stat1 protein, allowing for more efficient interferon signaling. This could lead to improved therapeutic benefits and reduced side effects for patients with hepatitis C, multiple sclerosis, and other conditions.
Researchers have discovered a novel mechanism used by tick-borne flaviviruses to counteract the natural ability of interferon to combat the virus. The study found that NS5 protein blocks immune defenses, preventing the immune system from stopping the spread of the virus and helping the body recover from infection.
Researchers developed a hyper-responsive Stat1 molecule to amplify the body's immune response without side effects. This improvement could lead to treatments for viral infections, cancer, and other conditions with lower doses of interferon.
Researchers found that activated STAT5 in melanoma cells blocks interferon's ability to inhibit growth, leading to frequent treatment failure. Analyzing STAT5 status may help personalize therapies for advanced melanoma patients.
Researchers found asthmatics produce lower levels of interferon beta, making them more susceptible to respiratory virus infections. A potential new treatment for asthma attacks involves using a device to top up interferon levels in the lungs.
Researchers at NYU studied the body's response to viral encephalitis and found that neurons are sensitive to protective effects of type I interferons. Interferons induce pathways to fight the virus' spread but can be ineffective in certain stages, leaving infected neurons vulnerable.
Researchers found that adding a vaccine targeting the Philadelphia chromosome protein can reduce residual disease and increase molecular response in patients with chronic myeloid leukaemia. The vaccine was shown to be effective in combination with imatinib and interferon alfa treatments.
A new study identifies a genetic variant associated with increased MS risk in women, suggesting that interferon gamma production plays a key role in the disease. The findings provide potential targets for future research and treatments, as well as insights into gender differences in disease susceptibility.
Researchers have identified two genes in the interferon system strongly associated with SLE. Genetic variants of a thyrosinkinase enzyme may protect against the disease by blocking the interferon effect. The study, involving nearly 2,000 individuals, provides new insights into SLE mechanisms and potential treatment options.
Pegylated interferon-alpha shows promise in treating chronic hepatitis B infection, with higher sustained viral response rates compared to monotherapy. The study highlights the importance of hepatitis B virus genotype as a predictor of treatment response.
Researchers demonstrate that long-term maintenance therapy with peginterferon alfa-2b can prevent or delay the progression of hepatitis C, reducing the risk of liver damage by half. A new antiviral agent, NM283, also shows promising activity against genotype 1 HCV, offering hope for future therapies.
Researchers found that beta interferon significantly reduced brain tissue loss and slowed MS progression, with around a third of patients showing improved outcomes. The study's results suggest that beta interferon may be an effective treatment for delaying the progression of multiple sclerosis.
A new treatment combination of peginterferon and ribavirin has been shown to significantly improve viral control in patients with both HIV and hepatitis C. The study found that 40% of patients treated with peginterferon achieved HCV clearance, compared to 12% on the standard interferon treatment.
Researchers have discovered that Toll-like receptor 9 (TLR9) plays a crucial role in coordinating the immune response to viral infections. In this study, Dr. Marco Colonna and colleagues found that TLR9 recognizes viruses in immune cells and activates natural killer cell responses.
Researchers have identified proteins that determine which mice succumb to mousepox and which do not. Strains resistant to infection produce type-1 cytokines, while susceptible ones produce type-2 cytokine IL-4. The discovery could enable better protection for humans against smallpox.
A phase II multicenter study evaluated a multiepitope CD8 T-cell vaccine for metastatic melanoma patients, demonstrating an immune response associated with longer survival. The vaccine showed promising results in stimulating an immune response, but no correlation was found with clinical tumor responses.
Researchers found that brain atrophy was detected on MRI more consistently than decline on cognitive tests or rating scales in patients with PCNSL. The study also examined the risk of stroke associated with triptan use in migraines, finding no increased risk.
A large trial found that interferon gamma-1b did not slow the progression of pulmonary fibrosis, but may improve survival in early-stage patients. The treatment's failure to prevent lung scarring was a major concern.
Researchers found that infants with reduced interferon gamma production at age 3 months and lower soluble CD14 levels at birth are 4.5 times more likely to develop recurrent wheezing. Chronic cough is also linked to abnormal release of inflammatory mediators within the airway, according to a separate study.
Researchers found that patients treated with corticosteroids plus interferon alfacon-1 experienced faster resolution of chest x-ray abnormalities and improved oxygen saturation levels compared to those treated with corticosteroids alone. This suggests that combination therapy may be a promising approach for treating SARS.
A new study published in the Journal of Clinical Oncology found that low-dose interferon therapy did not extend overall or recurrence-free survival in high-risk melanoma patients. The trial involved 674 patients and found that both groups experienced similar rates of disease recurrence and mortality.
A triple therapy study using ZADAXIN in combination with pegylated interferon alpha and ribavirin showed a 61% response rate for patients with hepatitis C who were non-responders to previous treatment. The study found that ZADAXIN improved response rates for these patients.
Patients developing neutralizing antibodies had longer time to first relapse and increased yearly relapse rate compared to antibody-negative patients. The presence of antibodies did not affect overall disease outcome, but prompt consideration for alternative treatments may be necessary.
A new clinical trial led by Duke University aims to compare the efficacy of two pegylated interferon treatments for hepatitis C virus. The IDEAL trial will enroll 2,880 patients and determine which treatment results in a sustained viral response in the largest proportion of patients.
Researchers found that recombinant interferons were effective against SARS-CoV replication, with interferon beta showing prophylactic protection and antiviral potential. Interferon alpha was less effective but could be a potential drug of choice in combination with other antiviral drugs.
A phase II study of a multiepitope CD8 T-cell vaccine has demonstrated promising results, inducing an immune response in 32% of patients with metastatic melanoma. The vaccine showed significant correlations with non-progression of disease and longer survival rates.
Researchers found that administering interferon alpha and gamma intranasally provided nearly full protection (over 95%) against a lethal vaccinia virus infection in mice. This suggests potential implications for using interferons as a prophylactic tool in aerosol orthopoxvirus infections.
A review of seven trials found that interferon may reduce exacerbations in relapsing-remitting multiple sclerosis patients in the first year, but its long-term effects are uncertain. Common side effects and toxic effects also occurred.
A study of 39 hepatitis C patients found that 33% developed interferon-induced major depression, but 84% improved with antidepressant treatment. The research challenges the common practice of discontinuing interferon therapy for depressed patients.